Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells

Cancer Biology and Therapy

Volumn 11, Issue 2, 2011, Pages 254-262

  Debinski, Waldemar ^a   Gibo, Denise M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Activating protein 1 (AP 1); EGF; Fos related antigen 1 (Fra 1); Gene expression; JunB; Knockdown; Malignant gliomas; Migration; Phosphorylation; Transactivation

Indexed keywords

EPIDERMAL GROWTH FACTOR; PHOSPHOPROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB;

ANTIGEN EXPRESSION; ARTICLE; CANCER MORPHOLOGY; CELL MIGRATION; CONTROLLED STUDY; CYTOARCHITECTURE; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLIOBLASTOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSFECTION; TRANSGENES;

EID: 78751552841     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.2.13953     Document Type: Article

References (26)

1. Levin VA, Sheline GH, Gutin PH. Neoplasms of the central nervous system. In: Cancer: principles and practice of oncology, Philadelphia: J.B. Lippincott Company 1989; 3:1557-611.
2. Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, et al. VEGF-D is an X-linked/AP-1-regulated onco-angiogen in highly vascularized tumors. Mol Med 2001; 7:598-608.
3. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 2005; 3:237-49.
4. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000; 36:1640-8.
5. Scott LA, Vass JK, Parkinson EK, Gillespie DAF, Winnie JN, Ozanne BW. Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization and the tumor suppressor p16INK4a and p53. Mol Cell Biol 2004; 24:1540-59.
6. Young MR, Colburn NH. Fra-1: a target for cancer prevention or intervention. Gene 2006; 379:1-11.
7. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factorreceptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91:484-8.
8. Battista S, de Nigris F, Fedele M, Chiappetta G, Scala S, Vallone D, et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 1998; 17:377-85.
9. Zoumpourlis V, Papassava P, Lindardopoulos S, Gillespie D, Balmain A, Pintzas A. High levels of c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 2000; 19:4011-21.
10. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of β-catenin-T cellfactor/ lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci. USA 1999; 96:1603-8.
11. Bamberger AM, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, et al. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 1999; 84:533-8.
12. Tulchinsky E. Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol 2000; 15:921-8.
13. Schreiber M, Wand ZQ, Jochum W, Fetka I, Elliott C, Wagner EF. Placental vascularisation requires the AP-1 component Fra-1. Development 2000; 127:4937-48.
14. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20:2401-12.
15. Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E, Berezin V. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 2003; 22:5045-54.
16. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998; 18:7095-105.
17. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4:67-79.
18. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 1995; 15:3748-58.
19. Andersen H, Mahmood S, Tkach V, Cohn M, Kustikova O, Grigorian M, et al. The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials. Oncogene 2002; 21:4843-8.
20. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genetics 2000; 24:184-7.
21. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005; 24:1434-44.
22. Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res 2007; 67:6204-11.
23. Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 2003; 63:3539-45.
24. Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M, et al. Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J 2007; 26:1878-90.
25. Hurd TW, Culbert AA, Webster KJ, Tavare' JM. Dual role for mitogen-activated protein kinase (Erk) in insulin-dependent regulation of Fra-1 (fos-related antigen-1) transcription and phosphorylation. Biochem J 2002; 368:573-80.
26. Wykosky J, Gibo DM, Stanton C, Debinski W. IL-13 Receptor alpha-2, EphA2 and Fra-1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008; 14:199-208.